Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Amortizatization of Intangibles: 2017-2021

Historic Amortizatization of Intangibles for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2021 value amounting to $113,000.

  • Apellis Pharmaceuticals' Amortizatization of Intangibles fell 99.98% to $3,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $113,000, marking a year-over-year decrease of 99.25%. This contributed to the annual value of $113,000 for FY2021, which is 99.25% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Amortizatization of Intangibles of $113,000 as of FY2021, which was down 99.25% from $15.0 million recorded in FY2020.
  • Over the past 5 years, Apellis Pharmaceuticals' Amortizatization of Intangibles peaked at $15.0 million during FY2020, and registered a low of $13,563 during FY2017.
  • For the 3-year period, Apellis Pharmaceuticals' Amortizatization of Intangibles averaged around $5.2 million, with its median value being $356,000 (2019).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first skyrocketed by 4,108.71% in 2020, then tumbled by 99.25% in 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' Amortizatization of Intangibles (Yearly) stood at $13,563 in 2017, then surged by 429.32% to $71,791 in 2018, then surged by 395.88% to $356,000 in 2019, then spiked by 4,108.71% to $15.0 million in 2020, then plummeted by 99.25% to $113,000 in 2021.